Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
for Non-Small Cell Lung Cancer, NSCLC
28 locations incl. Gilbert
Sponsor: Revolution Medicines, Inc.
Sex: All·Age: 18+
Code: NCT06162221·Phase 1, Phase 2·Recruiting·Listed Dec 2023